Consort Medical said the first product to use its built-in dose counter had been given the go-ahead by the US Food and Drug Administration.
Consort's Integrated Dose Counter (IDC) is being used in Teva's QNASL nasal aerosol, which treats of nasal seasonal allergy symptoms.
The firm had been developing its IDC for several years in response to a patient and compliance need to let patients know if their device contained sufficient drug and to indicate when they need to seek a further prescription.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
It provides patients with an indication of how many doses are left inside the canister in line with FDA guidance.
"We are very pleased to announce that the FDA has approved the use of our IDC with Teva's QNASL, making this our first commercially marketed integrated dose counter," said chief executive Jon Glenn.
-
FTSE 100 hits record highs – why is it rising and will we see more gains?Advice UK equities have been described as unloved for a long time but as the FTSE 100 hits new highs, we explain if now is the time to buy British.
-
How to invest in copperIt may be time to invest in copper as the red metal appears poised for a big jump. Dominic Frisby looks at what should investors should buy
